Cargando…

PB2049: THE EFFICACY OF HETROMBOPAG PLUS CYCLOSPORINE A IN PATIENTS WITH TRANSFUSION-DEPENDENT NON-SEVERE APLASTIC ANEMIA: A PROSPECTIVE REGISTRY STUDY

Detalles Bibliográficos
Autores principales:	Gong, Yuemin, Chen, Xiaoyu, Zhang, Xinyu, He, Guangsheng, LI, Jianyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429414/ http://dx.doi.org/10.1097/01.HS9.0000974996.55901.05

Ejemplares similares

PB2049: MEXICAN REGISTRY OF MYELOPROLIFERATIVE NEOPLASMS. INITIAL REPORT
por: De La Peña Celaya, J. A., et al.
Publicado: (2022)

PB2034: TARGETED SEQUENCING LANDSCAPE OF A CHINESE PURE RED CELL ANEMIA COHORT
por: LI, Yue, et al.
Publicado: (2023)

P792: CLINICAL STUDY OF HETROMBOPAG COMBINED WITH CYCLOSPORINE A IN THE TREATMENT OF CHILDREN WITH NON-SEVERE APLASTIC ANEMIA
por: Chang, Lixian, et al.
Publicado: (2023)

Transfusion-dependent non-severe aplastic anemia: characteristics and outcomes in the clinic
por: Zhang, Yawen, et al.
Publicado: (2023)

Hetrombopag plus porcine ATG and cyclosporine for the treatment of aplastic anaemia: early outcomes of a prospective pilot study
por: Yang, Wenrui, et al.
Publicado: (2023)

PB1950: MASS CYTOMETRY ANALYSIS IDENTIFIES T CELL IMMUNE SIGNATURE FOR APLASTIC ANEMIA AND PREDICTS RESPONSE TO CYCLOSPORINE
por: Zhang, L., et al.
Publicado: (2022)

PB2606: REAL-WORLD EXPERIENCE OF HETROMBOPAG IN RELAPSE AND REFRACTORY IMMUNE THROMBOCYTOPENIA
por: Feng, Yimei, et al.
Publicado: (2023)

P763: EFFICACY AND SAFETY OF AVATROMBOPAG IN THE TREATMENT OF TRANSFUSION-DEPENDENT NON-SEVERE APLASTIC ANEMIA
por: Zhang, Ting, et al.
Publicado: (2023)

PB2621: TREATMENT OF IMMUNE THROMBOCYTOPENIA WITH HETROMBOPAG—A SINGLE-CENTER RETROSPECTIVE, OBSERVATIONAL STUDY
por: Zhou, Hu, et al.
Publicado: (2023)

PB2055: PREGNANCY IN PATIENTS WITH APLASTIC ANEMIA – CLINICAL OBSERVATIONS
por: Shilova, Elene, et al.
Publicado: (2023)

PB2048: HEMATOLOGIC RECOVERY INDUCED BY AVATROMBOPAG IN SAA REFRACTORY OR INTOLERANT TO IMMUNOSUPPRESSIVE THERAPY COMBINED WITH ELTROMBOPAG
por: Liu, Xiaoqing, et al.
Publicado: (2023)

PB2037: NEW TERT VARIANT IN A FAMILY WITH APLASTIC ANEMIA
por: Virijevic, Marijana, et al.
Publicado: (2023)

PB1932: GENERIC ELTHROMBOPAG WITH STANDARD IMMUNOSUPPRESSIVE THERAPY IN SEVERE APLASTIC ANEMIA
por: Ranjit Kumar, C., et al.
Publicado: (2022)

A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy
por: Peng, Guangxin, et al.
Publicado: (2022)

PB1935: MANAGEMENT OF NON-SEVERE APLASTIC ANEMIA: LABORATORY WORKUP AND TREATMENT PATTERNS.
por: Cassanello, G., et al.
Publicado: (2022)

PB2066: SYSTEMIC LUPUS ERYTHEMATOSUS-INDUCED AMEGAKARYOCYTIC THROMBOCYTOPENIA AND SUBSEQUENT APLASTIC ANEMIA
por: Seong, Gyuhee, et al.
Publicado: (2023)

PB1940: ACQUIRED APLASTIC ANEMIA: THE CHALLENGE OF TREATMENT IN MEXICO. SINGLE HEMATOLOGY CENTER EXPERIENCE
por: Guajardo Leal, M. L., et al.
Publicado: (2022)

PB2065: SEVERE HEMOLYSIS OF PNH PATIENTS ASSOCIATED WITH OMICRON INFECTION IN CHINA
por: Yang, Hui, et al.
Publicado: (2023)

PB2046: CHANGINGS IN GENETIC DEFINITION AND MANAGEMENT OF ACQUIRED APLASTIC ANEMIA: A SINGLE CENTER EXPERIENCE
por: Bortolotti, Marta, et al.
Publicado: (2023)

PB2038: THE POTENTIAL MECHANISM OF TCM TREATMENT OF CHRONIC APLASTIC ANEMIA BASED ON DATA MINING AND NETWORK PHARMACOLOGY
por: Si, Yuping, et al.
Publicado: (2023)

PB2069: ELTROMBOPAG WITH IMMUNO SUPPRESSIVE THERAPY IN SEVERE ACQUIRED APLASTIC ANEMIA IN CHILDREN AND ADOLESCENTS: A MONOCENTRIC EXPERIENCE
por: Sayed, Nesrine Ben, et al.
Publicado: (2023)

PB2041: COMPARISON OF ELTROMBOPAG AND AVATROMBOPAG IN THE TREATMENT OF REFRACTORY/RELAPSED APLASTIC ANEMIA, A SINGLE CENTER STUDY IN CHINA
por: Zhang, Zhuxin, et al.
Publicado: (2023)

PB1941: PRELIMINARY EXPLORATION OF PROLONGED USE OF ELTROMBOPAG IN PATIENTS WITH NAÏVE SEVERE APLASTIC ANEMIA IN THE REAL WORLD: DURATION AND EFFICACY
por: Li, R., et al.
Publicado: (2022)

PB2479: ELTROMBOPAG, BUT NOT AVATROMBOPAG, REGULATES BONE MARROW MICROENVIRONMENT MIMICKING APLASTIC ANEMIA THROUGH DOWN-REGULATION OF FERROPTOSIS INHIBITOR
por: Ji, Jiang, et al.
Publicado: (2023)

Cyclosporine Therapy in Patients with Transfusion-independent Non-severe Aplastic Anemia: A Retrospective Analysis
por: Matsuda, Kensuke, et al.
Publicado: (2018)

PB2550: EXPLORATION OF B-CELL RECEPTOR AND T-CELL RECEPTOR REPERTOIRES REVEALS DISTINCT MECHANISMS IN PURE RED CELL APLASIA, AUTOIMMUNE HEMOLYTIC ANEMIA AND APLASTIC ANEMIA
por: Zhang, Ruoxi, et al.
Publicado: (2023)

Immunomodulation Therapy for Severe Aplastic Anemia: —ALG Versus ALG Plus Cyclosporin A—
por: Park, Chong Won, et al.
Publicado: (1989)

PB2050: COMPARISON OF CLINICAL CHARACTERISTICS OF CHILD AND ADULT PATIENTS WITH PNH: ——TEN-YEAR FOLLOW-UP
por: Yang, Hui, et al.
Publicado: (2023)

PB2466: PERIPHERAL BLOOD AS GRAFT SOURCE FOR APLASTIC ANEMIA TRANSPLANT: OUTCOMES OF YOUNG ADULTS AND ADULTS IN A MEXICAN PUBLIC HOSPITAL
por: Sotomayor Duque, Guillermo, et al.
Publicado: (2023)

PB2067: PROSPECTIVE SELF-CONTROL ANALYSIS OF GLUCOCORTICOID MAINTENANCE THERAPY FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
por: Yang, Hui, et al.
Publicado: (2023)

PB2431: OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA IN PEDIATRIC POPULATION - A SINGLE CENTER EXPERIENCE FROM PUBLIC HOSPITAL
por: Patil, Rajesh, et al.
Publicado: (2023)

PB2471: EFFECT OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MODIFIED FC PRETREATMENT REGIMEN ON SEX HORMONE LEVELS IN CHILDREN WITH SEVERE APLASTIC ANEMIA
por: MA, Liangming, et al.
Publicado: (2023)

PB2252: A PATIENT WITH SEVERE APLASTIC ANEMIA UNDERWENT ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION. EVIDENCE-BASED NURSING CARE OF PATIENTS COMPLICATED WITH ORAL AND LABIAL TISSUE ULCERATION
por: Wang, LI, et al.
Publicado: (2023)

PB2428: CLINICAL EFFICACY AND HEALTH-RELATED QUALITY OF LIFE IN SEVERE APLASTIC ANEMIA TREATED BY UMBILICAL CORD BLOOD TRANSPLANTATION: A CROSS-SECTIONAL SURVEY IN CHINA
por: LI, Ping, et al.
Publicado: (2023)

PB1949: ELTROMBOPAG IN CHINESE PATIENTS WITH REFRACTORY OR RELAPSED SEVERE APLASTIC ANEMIA: A NON-RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II STUDY ASSESSING THE SAFETY AND EFFICACY OF ELTROMBOPAG
por: Chang, H., et al.
Publicado: (2022)

Cyclosporine monotherapy for severe aplastic anemia: a developing country experience
por: Al-Ghazaly, Jameel, et al.
Publicado: (2005)

Effective treatment of aplastic anemia secondary to chemoradiotherapy using cyclosporine A
por: Ruan, Jing, et al.
Publicado: (2021)

Population Pharmacokinetics of Cyclosporine in Chinese Pediatric Patients With Acquired Aplastic Anemia
por: Gao, Xuan, et al.
Publicado: (2022)

PB2287: END OF LIFE TRANSFUSIONS IN PATIENTS WITH AN ONCOLOGICAL DIAGNOSIS
por: Duque, L., et al.
Publicado: (2022)

P773: CYCLOPHOSPHAMIDE COMBINED WITH PREDNISONE FOR CYCLOSPORINE-REFRACTORY/RELAPSED T-LARGE GRANULAR LYMPHOCYTE LEUKEMIA ASSOCIATED PURE RED CELL APLASIA
por: Liu, Xiaoqing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_55o8p1capm07toahopokcae8v1